COMMUNIQUÉS West-GlobeNewswire

Vistin Pharma ASA: Invitation to Q2 2026 conference call
13/08/2026
Oslo, Norway, 13 August 2026 Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other [...]
Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
13/08/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 [...]
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08/2026
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan [...]
Zealand Pharma Announces Financial Results for the First Half of 2026
13/08/2026
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum [...]
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
13/08/2026
Ventes totales de produits de 64,0 millions d’euros o En ligne avec les attentes ; confirmation de la prévision annuelle de ventes comprises entre 135 et 150 millions d’euros. Solide position de trésorerie de 121,5 [...]
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
13/08/2026
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and [...]
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
13/08/2026
U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target [...]
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
13/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Rampart retire son recours contre la décision d’invalidation de l’USPTO
12/08/2026
ST. PAUL, Minnesota, 12 août 2026 (GLOBE NEWSWIRE) -- Egg Medical a annoncé que Rampart IC, LLC (« Rampart ») avait retiré son recours contre la décision de réexamen de l’USPTO, selon laquelle les revendications du [...]
Earth Science Tech, Inc. (ETST) Expands National Footprint with Strategic Acquisition of California Compounding Pharmacy, Meduvo LLC
12/08/2026
MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Meduvo LLC, a [...]
Hyperion DeFi Reports 2Q 2026 Financial Results with Another Record Quarterly Net Income and Strong Operating Momentum
12/08/2026
Company Reports Record $31.0M Net Income and $53.7M Adjusted EBITDA ( 8 ) Announcing New HAUS Agreement with Entropy, an Upcoming HIP-3 Deployer 1 Million HYPE Tokens Redeployed to Support HIP-3 & HIP-4 Markets [...]
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
12/08/2026
PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed sales subject to [...]
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
12/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
12/08/2026
Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi ® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and [...]
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
12/08/2026
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebipenem [...]
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
12/08/2026
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose [...]
Acquisition of Own Shares
12/08/2026
Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Kura Oncology Reports Second Quarter 2026 Financial Results
12/08/2026
– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share of new patient starts in R/R NPM1- [...]
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08/2026
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in [...]

Pages